Patent Yard Sign in
Expired Canadian patentCanada

Substituted imidazolyl-alkyl-piperazine and-diazepine derivatives

CA 1320199 C · Owner: Pinhas, Henri · Inventors: Beranger, Serge; Lee, Chi-Ho; Alps, Brian J.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A:, FORMULA A wherein:, R1 is aryl;, R2 is aryl, lower alkyl or hydrogen;, R3 is lower alkyl, hydroxy or hydrogen;, R4 is aryl;, R5 is aryl; m is two or three;, n is zero, one or two provided that when R3 is hydroxy, n is one or two; and, q is zero, one, two, or three; and the pharmaceutically acceptable salts thereof are, useful for treating mammals having a variety of disease states, such as stroke, epilepsy or epileptic psychotic symptoms, hypertension, angina, migraine arrhythmia, thrombosis, embolism, acute cardiac failure irritable, bowel syndrome, neurodegenerative diseases such as Alzheimer's or …

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Granted July 13, 1993. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended July 13, 2010.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledApril 22, 1988
GrantedJuly 13, 1993
Term endedJuly 13, 2010
Patent numberCA 1320199 C
Classification (IPC)C07D403/06 +2 more

Timeline

Timeline From CIPO dates

19891992199519982001200420072010Application filedApril 22, 1988Patent grantedJuly 13, 1993Term endedJuly 13, 2010

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.